| Literature DB >> 26416753 |
John A Howe1, Hao Wang1, Thierry O Fischmann1, Carl J Balibar1, Li Xiao1, Andrew M Galgoci1, Juliana C Malinverni1, Todd Mayhood1, Artjohn Villafania1, Ali Nahvi2, Nicholas Murgolo1, Christopher M Barbieri1, Paul A Mann1, Donna Carr1, Ellen Xia1, Paul Zuck3, Dan Riley3, Ronald E Painter1, Scott S Walker1, Brad Sherborne1, Reynalda de Jesus1, Weidong Pan1, Michael A Plotkin1, Jin Wu1, Diane Rindgen1, John Cummings1, Charles G Garlisi1, Rumin Zhang1, Payal R Sheth1, Charles J Gill1, Haifeng Tang1, Terry Roemer1.
Abstract
Riboswitches are non-coding RNA structures located in messenger RNAs that bind endogenous ligands, such as a specific metabolite or ion, to regulate gene expression. As such, riboswitches serve as a novel, yet largely unexploited, class of emerging drug targets. Demonstrating this potential, however, has proven difficult and is restricted to structurally similar antimetabolites and semi-synthetic analogues of their cognate ligand, thus greatly restricting the chemical space and selectivity sought for such inhibitors. Here we report the discovery and characterization of ribocil, a highly selective chemical modulator of bacterial riboflavin riboswitches, which was identified in a phenotypic screen and acts as a structurally distinct synthetic mimic of the natural ligand, flavin mononucleotide, to repress riboswitch-mediated ribB gene expression and inhibit bacterial cell growth. Our findings indicate that non-coding RNA structural elements may be more broadly targeted by synthetic small molecules than previously expected.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26416753 DOI: 10.1038/nature15542
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962